<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1426">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771351</url>
  </required_header>
  <id_info>
    <org_study_id>AMG-COV-202</org_study_id>
    <nct_id>NCT04771351</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19</brief_title>
  <official_title>A Randomized, Blinded-controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adult Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo-controlled study to investigate the safety and efficacy of a single&#xD;
      injection of COVI-AMG in inpatient adults with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled study designed to&#xD;
      investigate the safety and efficacy of a single injection of COVI-AMG in inpatient adults&#xD;
      with COVID-19. Subjects will receive 100 mg of COVI-AMG, 200 mg of COVI-AMG, or placebo via&#xD;
      slow IV push. Subjects will be followed for approximately 70 days post dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who are alive and free of respiratory failure at Day 29</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Proportion of subjects who are alive and free of respiratory failure at Day 29</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load reduction</measure>
    <time_frame>Baseline to Day 4, 15, and 29</time_frame>
    <description>Log-10 viral load reduction from baseline to Day 4, Day 15, and Day 29 by nasopharyngeal RT-PCR test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sustained clinical improvement</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Time to sustained clinical improvement defined as achieving a score of ≤2 on the Ordinal Scale for Clinical Improvement (OSCI) for a continuous period of 48h and maintained to Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with clinical improvement</measure>
    <time_frame>Baseline to Day 15 and 29</time_frame>
    <description>Proportion of subjects with clinical improvement defined as ≤2 on the OSCI at Day 15 and Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at Day 29</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>All-cause mortality at Day 29</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVI-AMG 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of 100 mg of COVI-AMG will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVI-AMG 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of 200 mg of COVI-AMG will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single injection of placebo will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVI-AMG</intervention_name>
    <description>COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)</description>
    <arm_group_label>COVI-AMG 100 mg</arm_group_label>
    <arm_group_label>COVI-AMG 200 mg</arm_group_label>
    <other_name>STI-2020</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Diluent solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive for COVID-19 by an approved antigen test&#xD;
&#xD;
          -  Progressive disease suggestive of ongoing COVID-19 infection&#xD;
&#xD;
          -  Requires hospitalization for acute medical care&#xD;
&#xD;
          -  Provides written informed consent&#xD;
&#xD;
          -  Willing to follow contraception guidelines during study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requires high-flow oxygen supplementation&#xD;
&#xD;
          -  Current or imminent respiratory failure&#xD;
&#xD;
          -  Has rapidly progressing symptoms that in the investigator's opinion are likely to&#xD;
             progress to needing high-flow oxygen or to respiratory failure within 24 to 48 hours&#xD;
&#xD;
          -  Any condition which, in the investigator's opinion, participation would not be in the&#xD;
             subject's best interest or could prevent, limit, or confound the protocol-specified&#xD;
             assessments&#xD;
&#xD;
          -  Has participated, or is participating in, a clinical research study evaluating&#xD;
             COVID-19 convalescent plasma, monoclonal antibodies against SARS-CoV-2, or intravenous&#xD;
             immunoglobulin within 3 months or less than 5 half-lives of the investigational&#xD;
             product (whichever is longer)&#xD;
&#xD;
          -  Pregnant or lactating and breast feeding, or planning on either during the study&#xD;
&#xD;
          -  Unable to comply with planned study procedures and be available for all follow-up&#xD;
             visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Royal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mike Royal, MD</last_name>
    <phone>(858) 203-4100</phone>
    <phone_ext>4146</phone_ext>
    <email>mroyal@sorrentotherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Teradan Clinical Trials</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Lorch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Lorch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid-19</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

